๐ฌDeep Research
VSTM โ Verastem Inc ยท catalysts, narrative & risks
Verastem Oncology (VSTM) โ Point-in-Time Research Summary (as of Oct 21, 2026)
Company profile: Verastem, Inc. (trading as Verastem Oncology; Nasdaq: VSTM; ISIN US92337C2035) is a Needham, Massachusetts-based development-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. Its portfolio includes an FDA-approved combination (avutometinib + defactinib, marketed as AVMAPKI FAKZYNJA CO-PACK) and an in-development oral KRAS G12D inhibitor, VS-7375. [24], [21], [22], [26]
Key recent catalysts (last ~1โ3 months)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ